CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD

Similar documents
TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Fort Detrick, Maryland

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

Award Number: W81XWH

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Approved for public release; distribution unlimited

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

Award Number: W81XWH

Expression and Promoter Methylation of P16INK4A During Estrogen-Induced Mammary Carcinogenesis in the ACI Rat. Omaha, NE

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

Detection of Prostate Cancer Progression by Serum DNA Integrity

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

La Jolla, CA Approved for Public Release; Distribution Unlimited

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

CONTRACTING ORGANIZATION: Cleveland Clinic Foundation Cleveland, OH 44195

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

Award Number: W81XWH TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Homeostatic and Circadian Abnormalities in Sleep and Arousal in Gulf War Syndrome

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Prostate Expression Databases: Gene Expression Resources for Comparative Studies of Prostate Carcinogenesis

Award Number: W81XWH TITLE: "Longitudinal Study of a Novel Performance-based Measure of Daily Function."

TITLE: Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cells

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

TITLE: Gulf War Illness Evaluation of an innovative detoxification program

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center Nashville, TN

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: UNIVERSITY OF ILLINOIS Chicago, IL 60612

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Maximizing Energy After Traumatic Brain Injury: A Novel Intervention

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

TITLE: Improving Work Outcomes for Veterans with Traumatic Brain Injury. San Diego, CA 92161

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland X Approved for public release; distribution unlimited

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Approved for public release; distribution unlimited

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030

AD (Leave blank) PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

Final Performance Report. Contract # FA C-0006: Hearing Protection for High-Noise Environments Period of Performance: Oct 01, 2007 Nov 30, 2009

CONTRACTING ORGANIZATION: Southern Illinois University School of Medicine, Springfield, IL

TITLE: Post-Traumatic Headache and Psychological Health: Mindfulness Training for Mild Traumatic Brain Injury

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Veterans Medical Research Foundation San Diego, CA

CONTRACTING ORGANIZATION: West Virginia University Morgantown, West Virginia

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

TITLE: Genetic and Epigenetic Differences in Monozygotic Twins with NF1

Promote Adjustment during Reintegration following Deployment

Co-PI: Amy Trentham-Dietz, PhD

Transcription:

AD Award Number: DAMD17-01-1-0713 TITLE: Proton MR Spectroscopic Imaging in NF1 PRINCIPAL INVESTIGATOR: Peter B Barker, D.Phil. CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205-2196 REPORT DATE: July 2006 TYPE OF REPORT: Final PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE 2. REPORT TYPE 01-07-2006 Final 3. DATES COVERED 1 Jul 2001 30 Jun 2006 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER Proton MR Spectroscopic Imaging in NF1 5b. GRANT NUMBER DAMD17-01-1-0713 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5d. PROJECT NUMBER Peter B Barker, D.Phil. 5e. TASK NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Johns Hopkins University School of Medicine Baltimore, MD 21205-2196 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES Original contains colored plates: ALL DTIC reproductions will be in black and white. 14. ABSTRACT Neurofibromatosis Type 1 (NF-1) is the most common autosomal dominant genetic disorder, affecting the skin, central (CNS) and peripheral nervous systems. Children with NF-1 have an increased risk of developing significant learning disability (LD), cognitive impairment, and optic or brain stem gliomas. Cerebral magnetic resonance imaging (MRI) in NF-1 reveals regions of high signal intensity (often called unidentified bright objects, or UBOs). The pathophysiology of UBOs is poorly understood, and it is controversial to what extent they are involved in cognitive impairment. The aims of this proposal are to characterize the underlying metabolic abnormalities in NF-1 with proton MR spectroscopic imaging (MRSI). We have developed a rapid, quantitative MR spectroscopic imaging (MRSI) protocol for the evaluation of cerebral metabolite levels in NF-1. Metabolite levels will be determined both in UBOs and other brain regions, both in order to improve understanding of the etiology of UBOs, and to understand the relationship between regional brain metabolism and LD. 60 subjects with NF1 and 60 control subjects will be evaluated with proton MRSI and detailed neuropsychological testing. Ultimately, proton MRSI may be a useful test for identifying children with NF-1 at risk of developing LD, and also help in distinguishing UBOs from other, malignant lesions which require therapeutic intervention. 15. SUBJECT TERMS Neurofibromatosis Type 1, Magnetic Resonance Spectroscopy, Magnetic Resonance Imaging, Diagnosis 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES a. REPORT U b. ABSTRACT U c. THIS PAGE U UU 12 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code) Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18

Table of Contents Cover 1 SF 298 2 Table of Contents 3 Introduction 4 Body 5 Key Research Accomplishments 8 Reportable Outcomes 9 Conclusions 10 References 11 Appendices 12

Introduction Neurofibromatosis Type 1 (NF-1) is the most common autosomal dominant genetic disorder, affecting the skin, central (CNS) and peripheral nervous systems. Children with NF-1 have an increased risk of developing significant learning disability (LD), cognitive impairment, and optic or brain stem gliomas. While phenotypic expression is variable, a common concern of parents of children with NF-1 is presence of learning disabilities (LD). Although the cognitive profile of NF-1 is similar to that of children with learning disabilities in the general population, with weaknesses in language, reading, and executive function commonly noted, an unusual aspect of the NF-1 profile is visuospatial impairment, which is almost always reported in NF-1 (Levine et al., 2006). Our preliminary data used proton magnetic resonance spectroscopic imaging (MRSI), a method that allows for examination of neurochemical profiles in specific regions of the brain, reported metabolic abnormalities in the thalamus of children with NF-1 (Wang et al., 2000); however, the relationship of these findings with cognition in NF-1 was unknown at that time. Proton magnetic resonance spectroscopic imaging (MRSI) is a relatively new, non-invasive metabolic imaging technique that can provide information about the cellular composition and metabolism of brain tissue. Our preliminary proton MRSI data in NF-1 indicated highly significant perturbations in thalamic metabolism in NF-1, regardless of presence or absence of abnormalities on conventional magnetic resonance imaging (MRI) known as unidentified bright objects, or UBOs (Wang et al, 2000). UBOs themselves were metabolically more similar to normal brain tissue. These data indicated a dissociation between imaging and metabolic findings, with more widespread cerebral involvement in NF-1 depicted using MRSI than that indicated by MRI. In this proposal, we extended these preliminary findings to confirmed that: (1) thalamic metabolism is abnormal in NF-1, (2) proton MRSI measures of thalamic metabolism correlate with neuropsychological performance, and (3) metabolic abnormalities in NF-1 are more diffuse and widespread than abnormalities visualized by MRI. The study design to test these hypotheses involved the performance of proton MRSI, MRI and neuropsychological testing in with NF-1 and age-matched control subjects. To test hypothesis (1), thalamic metabolite levels were compared between NF-1 subjects and controls. To test hypothesis (2) thalamic metabolite levels in NF-1 patients were correlated with results of a battery of neuropsychological tests, and for (3), metabolite levels in multiple regions of interest throughout the brain regions covered by MRSI were compared between NF-1 patients and controls. 4

Body To understand the linkages between the neurochemical abnormalities and cognition (in addition to replicating previous findings of abnormal thalamic metabolism in children with NF-1) the current study focused on examining the relationship between MRSI metabolite ratios and cognition, specifically visuospatial processing. Participants: 16 children with NF-1 [7 F; Overall AGE: 10.71 ± 2.73], and 35 children without NF-1 [5 F; Overall AGE: 9.89 ± 2.50] were included in the final analyses. Judgment of Line Orientation (JLO): This untimed visuospatial task requires the participant to decide the spatial relationship between two lines compared to a reference of a protractor-like half-circle of 11 lines. Scores are computed by tallying the number of correct responses, with a total possible score of thirty. Boston Naming Test (BNT): This untimed lexical access task requires naming of line-drawn objects. The 60-item test provides a measure of word retrieval efficiency as well as efficacy of semantic and phonemic cueing. Errors are broken down by type (phonemic, semantic, sequencing, circumlocution, and omission), and give information about the nature of the retrieval problem. MRSI Data Collection: All MR studies were performed on a Philips 1.5T Gyroscan MR scanner using the transmit-receive head coil. Prior to MRSI, a conventional brain MRI was performed consisting of sagittal T1-weighted images, and axial FLAIR and FSE T 2 scans. MR spectroscopic imaging was performed using a spin-echo sequence with two-dimensional phase-encoding and outer-volume saturation pulses for lipid suppression (2). Three 15 mm thick slices were recorded, with the middle slice placed at the level of the thalamus, and lower slices covering the brain stem and posterior fossa (common locations of UBOs in NF1) and the upper slice extending to the centrum semiovale. TR/TE was 1850/280 msec. A 28 by 28 circular phase-encoding scheme gave a total data acquisition time of 20 minutes (1 signal average per phaseencode step). The field-of-view was 24 cm, giving a nominal voxel size of 15.0x8.6x8.6 mm ( 1.1 cm 3 ). The echo signal was digitized with 256 data points and a spectral width of 1000 Hz. Watersuppression was accomplished with a single CHESS pulse with a bandwidth of 135 Hz. Extra-cranial lipid signals were attenuated by the use of 8 outer-volume saturation pulses, arranged in an octangular pattern to match the contours of the skull. T 1 -weighted MR images were recorded at the same slice locations as the MRSI data set for anatomical correlation. Prior to MRSI, shimming was performed to optimize field homogeneity, and water suppression optimized. After the MRSI acquisition, a final set of 5

double gradient-echo images were also recorded at the same slice locations in order to calculate maps of the B 0 magnetic field strength. MRSI Analyses: Spectroscopic imaging data were reconstructed using inhouse software ( csx3 ). Multi-slice 2D MRSI data sets were processed via 3D Fourier transformation with cosine and Fermi filters in the spatial (phase-encoding) domains, and exponential line broadening of 3 Hz, zero-filling to 2048 data points, and a high-pass convolution filter to remove the residual water signal (50 Hz stop-band) in the time-domain. Baseline correction was performed using a cubic spline routine. After setting the chemical shift of NAA to 2.02 ppm, spectroscopic images were created by numerical integration over the following frequency ranges: Choline (3.34 to 3.14 ppm), Creatine (3.14 to 2.94 ppm), and NAA (2.22 to 1.82 ppm). Spectra from the ROIs were bilaterally evaluated by numerical integration, and ratios of metabolite peaks were calculated. The following ROIs were chosen for analysis: brain stem, cerebellum, striatum, occipital white matter, mesial occipital cortex, centrum semiovale, parietal white matter, parietal gray matter and thalamus. A student t-test was used to evaluate between group differences (NF1 vs. controls), while regression analyses performed to determine correlations between metabolite ratios and neuropsychological test scores. A P-value of less than 0.05 considered significant. Results: Figure 1 shows thalamic spectra from one NF1 and one control, while Figure 2 shows metabolic images from an NF1 subject at the level of the thalamus. Figure 3 shows regression analyses for JLO versus selected metabolite ratios in NF1 and controls. Lower NAA/Cr and NAA/Cho ratios in the thalamus (p=0.017 and 0.04 respectively) and in the parietal white matter (p=0.04 and 0.039 respectively) in NF1 6

compared to the controls. There were significant positive correlations between JLO and NAA/Cho in the brain stem, cerebellum, occipital white matter (p=0.004, 0.001, 0.019 respectively). In addition, there were significant positive correlations between JLO and NAA/Cr in the brain stem, striatum and thalamus (p=0.018, 0.03, 0.016 respectively), and a significant negative correlation between JLO and Cho/Cr ratio in the cerebellum (p=0.015). A significant positive correlation between BNT and NAA/Cr and NAA/Cho was found in the brain stem (p=0.016, 0.009 respectively), and cerebellar NAA/Cho (p=0.02). Discussion Reduced ratios of NAA/Cho and NAA/Cr confirm the previous observation of abnormal thalamic metabolism (1), and suggest possible thalamic neuroaxonal loss or dysfunction in NF1. Abnormal thalamic metabolism in NF1 has also been reported using positron emission tomography (3). The current finding of reduced NAA/Cr and NAA/Cho in parietal white matter also suggests more widespread white matter involvement, consistent with a previous pathological study that found myelin vacuoles in NF1. JLO and BNT are tests of visuospatial skill and object naming, respectively, and previous studies have shown that patients with NF1 perform significantly worse on these tests compared to subjects without NF1. For this reason, these 2 tests were selected for comparison to MRSI data. JLO showed correlations with NAA/Cho and NAA/Cr in multiple brain regions, including the thalamus, striatum, brain stem and cerebellum, suggesting a link between widespread neuroaxonal dysfunction or loss in NF1 and abnormal visuospatial judgment. BNT also showed correlations with NAA/Cr and NAA/Cho ratios in brain stem and cerebellum. 7

Key Research Accomplishments Established MRSI and neuropsychological test methodology and collected data in NF1 and control subjects in the 6 to 16 year old age range. Statistical analysis shows significant metabolic differences between NF-1 and controls, both in the thalamus and other brain regions. These widespread metabolic changes correlated with reductions in both JLO and BNT scores, indicating an association with metabolic abnormalities and cognitive impairment. 8

Reportable Outcomes M. A. Mohamed, J. R. Abel, S. L. Rimrodt, L. E. Cutting, and P. B. Barker, ISMRM 14 th Annual Meeting, Seattle 2006, 2639, Proton MR Spectroscopic Imaging In Neurofibromatosis Type-1: Relationship To Neuropsychological Testing. J.R. Abel, S.T. Rimrodt, M.A. Mohamed, L.E. Cutting and P.B. Barker, 34 th Annual INS Meeting 2006, International Neuropsychological Society, Boston, MA Feb 2006, Magnetic Resonance Spectroscopic Imaging and NF-1: Correlates to Cognitive Function 9

Conclusions: In conclusion, proton MRSI, in addition to MRI, may help understand the pathophysiology of brain involvement in NF1, and its relationship to cognitive impairment and learning disabilities. The data presented here suggest that MRSI may have some role in evaluating children with NF-1 who are experiencing learning disabilities and being considered for therapeutic interventions, and that there is an underlying metabolic basis (perhaps reflecting changes in brain microstructure) for cognitive impairment in children with NF-1. 10

References 1. Wang PY, Kaufman WE, Koth CW, Denckla MB, Barker PB. Ann Neurol 47, 477-484 (2000). 2. Jacobs MA, Horská A, van Zijl PCM, Barker PB. Magn. Reson. Med. 46, 699-705 (2001). 3. Kaplan AM, Chen K, Lawson MA, Wodrich DL, Bonstelle CT, Reiman EM. J Child Neurol. 12: 499-506 (1997). 4. Levine TM, Materek A, Abel J, O'Donnell M, Cutting LE., Semin Pediatr Neurol. 2006 Mar;13(1):8-20. 11

Appendices None 12